RATIONALE: The effects of D-cycloserine (DCS) in animal models of anxiety disorders and addiction indicate a role for N-methyl D-aspartate (NMDA) receptors in extinction learning. Exposure/response prevention treatments for anxiety disorders in humans are enhanced by DCS, suggesting a promising co-therapy regime, mediated by NMDA receptors. Exposure/response prevention may also be effective in problematic drinkers, and DCS might enhance habituation to cues in these individuals. Since heavy drinkers show ostensible conditioned responses to alcohol cues, habituation following exposure/response prevention should be evident in these drinkers, with DCS enhancing this effect. OBJECTIVES: The objective of this study is to investigate the effect of DCS on exposure/response prevention in heavy drinkers. METHODS: In a randomised, double-blind, placebo-controlled study, heavy social drinkers recruited from the community received either DCS (125 mg; n = 19) or placebo (n = 17) 1 h prior to each of two sessions of exposure/response prevention. Cue reactivity and attentional bias were assessed during these two sessions and at a third follow-up session. Between-session drinking behaviour was recorded. RESULTS:Robust cue reactivity and attentional bias to alcohol cues was evident, as expected of heavy drinkers. Within- and between-session habituation of cue reactivity, as well as a reduction in attentional bias to alcohol cues over time was found. However, there was no evidence of greater habituation in the DCS group. Subtle stimulant effects (increased subjective contentedness and euphoria) which were unrelated to exposure/response prevention were found following DCS. CONCLUSIONS:DCS does not appear to enhance habituation of alcohol cue reactivity in heavy non-dependent drinkers. Its utility in enhancing treatments based on exposure/response prevention in dependent drinkers or drug users remains open.
RCT Entities:
RATIONALE: The effects of D-cycloserine (DCS) in animal models of anxiety disorders and addiction indicate a role for N-methyl D-aspartate (NMDA) receptors in extinction learning. Exposure/response prevention treatments for anxiety disorders in humans are enhanced by DCS, suggesting a promising co-therapy regime, mediated by NMDA receptors. Exposure/response prevention may also be effective in problematic drinkers, and DCS might enhance habituation to cues in these individuals. Since heavy drinkers show ostensible conditioned responses to alcohol cues, habituation following exposure/response prevention should be evident in these drinkers, with DCS enhancing this effect. OBJECTIVES: The objective of this study is to investigate the effect of DCS on exposure/response prevention in heavy drinkers. METHODS: In a randomised, double-blind, placebo-controlled study, heavy social drinkers recruited from the community received either DCS (125 mg; n = 19) or placebo (n = 17) 1 h prior to each of two sessions of exposure/response prevention. Cue reactivity and attentional bias were assessed during these two sessions and at a third follow-up session. Between-session drinking behaviour was recorded. RESULTS: Robust cue reactivity and attentional bias to alcohol cues was evident, as expected of heavy drinkers. Within- and between-session habituation of cue reactivity, as well as a reduction in attentional bias to alcohol cues over time was found. However, there was no evidence of greater habituation in the DCS group. Subtle stimulant effects (increased subjective contentedness and euphoria) which were unrelated to exposure/response prevention were found following DCS. CONCLUSIONS:DCS does not appear to enhance habituation of alcohol cue reactivity in heavy non-dependent drinkers. Its utility in enhancing treatments based on exposure/response prevention in dependent drinkers or drug users remains open.
Authors: Eric A Storch; Lisa J Merlo; Michael Bengtson; Tanya K Murphy; Mark H Lewis; Mark C Yang; Marni L Jacob; Michael Larson; Adam Hirsh; Melanie Fernandez; Gary R Geffken; Wayne K Goodman Journal: Int Clin Psychopharmacol Date: 2007-07 Impact factor: 1.659
Authors: Matt G Kushner; Suck Won Kim; Christopher Donahue; Paul Thuras; David Adson; Michael Kotlyar; James McCabe; Jillian Peterson; Edna B Foa Journal: Biol Psychiatry Date: 2007-06-22 Impact factor: 13.382
Authors: Michael W Otto; M Alexandra Kredlow; Jasper A J Smits; Stefan G Hofmann; David F Tolin; Rianne A de Kleine; Agnes van Minnen; A Eden Evins; Mark H Pollack Journal: Biol Psychiatry Date: 2015-09-25 Impact factor: 13.382
Authors: Kari A Mergenhagen; Bethany A Wattengel; Megan K Skelly; Collin M Clark; Thomas A Russo Journal: Antimicrob Agents Chemother Date: 2020-02-21 Impact factor: 5.191
Authors: T Schulte; Y-C Jung; E V Sullivan; A Pfefferbaum; M Serventi; E M Müller-Oehring Journal: Brain Imaging Behav Date: 2017-12 Impact factor: 3.978
Authors: Michael W Otto; Gladys N Pachas; Corinne Cather; Susanne S Hoeppner; Samantha J Moshier; Bridget A Hearon; Heather Burrell Ward; Alexandra B Laffer; Jasper A J Smits; A Eden Evins Journal: Cogn Behav Ther Date: 2018-08-16
Authors: Sunjeev K Kamboj; Alyssa Joye; Ravi K Das; Andrew J W Gibson; Celia J A Morgan; H Valerie Curran Journal: Psychopharmacology (Berl) Date: 2011-11-22 Impact factor: 4.530
Authors: M D Scofield; J A Heinsbroek; C D Gipson; Y M Kupchik; S Spencer; A C W Smith; D Roberts-Wolfe; P W Kalivas Journal: Pharmacol Rev Date: 2016-07 Impact factor: 25.468